RICHMOND, British Columbia,
July 27, 2017 /PRNewswire/ --
KEMRI Researchers show feasibility
of INSTI, a blood-based HIV home test
bioLytical Laboratories Inc., a leader in rapid diagnostic
assays, is pleased to share that its INSTI HIV Self Test was
featured at the 9th International AIDS Society
Conference on HIV Science (IAS 2017) in Paris as an oral presentation. The late
breaker abstract[1] highlighted
ground-breaking research into blood-based self-testing with INSTI,
creating a foundation for other researchers to build on. The
results were presented to an audience of several hundred delegates
from all over the world at the oral abstract session titled "Just
Do It Yourself: Preferences and Performances of HIV
Self-Testing".
The Kenya Medical Research Institute (KEMRI) researchers
conducted the INSTI HIV Self Test study in villages in Western Kenya from March to April of 2017 in
nearly 700 subjects from various backgrounds and with varying
levels of education and literacy. The study concluded that the
INSTI HIV Self Test, a simple to use blood-based test, performs
extremely well in low and middle income country populations, and it
was highly accepted by such intended users. Levels of accuracy and
overall usability of the INSTI HIV Self Test approached 99% in this
population. This real-life field study confirms that blood-based
self-testing with INSTI can be successfully applied in settings
where it can play an important role in identifying individuals and
their partners who may be living with HIV but are unaware of their
infection.
bioLytical is pleased that the KEMRI study abstract was selected
by IAS 2017 as a late breaker from many reputable abstract
submissions. The conference provided new insights into HIV disease
development, prevention and treatment where approximately 6,000
delegates from across the globe were in attendance.
"It is vital that studies like these are conducted, and the
results broadly reported, to demonstrate the safety and overall
utility of blood-based HIV self-tests in populations at risk for
HIV infection. bioLytical is extremely proud to have worked with
the researchers at KEMRI, led by Professor Matilu Mwau, in bringing
this important study to successful completion," said Rick Galli, bioLytical's Chief Technical
Officer.
About bioLytical Laboratories
bioLytical Laboratories is a privately owned Canadian company
engaged in the research, development and commercialization of
rapid, point-of-care in vitro medical diagnostics using its
proprietary INSTI™ technology platform. Today, the company
markets and sells its signature INSTI™ HIV test and has a
world-wide footprint of regulatory approvals including U.S. FDA
approval, Health Canada approval and CE mark from European
regulators. Their product provides a highly accurate HIV test
result in as little as 60 seconds translating into a compelling
value proposition for patients, healthcare professionals and public
health organizations. For more information on bioLytical
Laboratories, please visit http://www.biolytical.com.
[1]Mwau, M., Achieng, L, and Bwana,
P. Performance and Usability of INSTI, a Blood-based Rapid HIV
Self Test for Qualitative Detection of HIV Antibodies in Intended
Use Populations in Kenya. Kenya Medical Research Institute,
Nairobi, Kenya
Robert Mackie, +1-604-204-6784,
Info@biolytical.com